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Abstract
Alzheimer’s disease is a progressive and neurodegenerative disorder which involves multiple molecular
mechanisms. Intense research during the last years has accumulated a large body of data and the search for
sensitive and specific biomarkers has undergone a rapid evolution. However, the diagnosis remains problematic
and the current tests do not accurately detect the process leading to neurodegeneration. Biomarkers discovery and
validation are considered the key aspects to support clinical diagnosis and provide discriminatory power between
different stages of the disorder. A considerable challenge is to integrate different types of data from new potent
approach to reach a common interpretation and replicate the findings across studies and populations.
Furthermore, long-term clinical follow-up and combined analysis of several biomarkers are among the most
promising perspectives to diagnose and manage the disease. The present review will focus on the recent
published data providing an updated overview of the main achievements in the genetic and biochemical research
of the Alzheimer’s disease. We also discuss the latest and most significant results that will help to define a specific
disease signature whose validity might be clinically relevant for future AD diagnosis.
1. Background
Alzheimer’s disease (AD) is the most common form of
dementia and age-dependent neurodegenerative disorder.
It represents one of the major public health problems in
our modern age and epidemiological investigations esti-
mated that the amount of people with AD will rise to over
100 million by 2050 [1]. The main hallmarks of the disease
are decreased number of neurons, formation of amyloid
plaques and generation of neurofibrillary tangles which
results in neuronal dysfunction. Although a definitive diag-
nosis of AD is not possible until autopsy, diagnostic tools
to detect AD have improved considerably in recent years.
Even though there was significant technological advance,
improved antemortem AD diagnostic methods are still
needed. To date, early diagnosis of AD is difficult, there-
fore an important challenge for the successful manage-
ment of AD is the development of new tools to detect AD
in its earliest stages which could predict the progression of
the disease. In addition, it is necessary to translate neuro-
biological knowledge and biomarker research into clinical
practice. In this perspective, there is a significant effort to
discover novel candidate biomarkers that together with
those well established will be able to improve the accuracy
of diagnosis. Fortunately, there has been a significant pro-
gress toward the use of potent and modern methods
which allow the concomitant measurement of several bio-
markers but we are far to define and create a reliable diag-
nostic and prognostic profile.
According to the National Institute of Health, a biomar-
ker is “a characteristic that is objectively measured and
evaluated as an indicator of normal biologic processes,
pathogenic processes, or pharmacologic responses to a
therapeutic intervention” [2].
Nowadays there is still not an ideal biomarker able to
improve differential diagnosis, track disease progression
and measure treatment efficacy. This means that we have
an urgent need to develop biomarkers that are sensitive
and specific to AD pathology with positive and negative
predictive value for the disorder [3]. In addition, it is cru-
cial to understand the complex relationship between the
different biomarkers. The main tests for biomarkers
classes used in the diagnosis and prognosis of AD are posi-
tron emission tomography (PET) neuroimaging of b-amy-
loid (Ab) protein deposition, magnetic resonance imaging
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quantification of abundance of proteins in cerebrospinal
fluid (CSF) and blood (i.e., plasma and serum) especially
with quantitative proteomics strategies, genotyping of
genetic polymorphism and finally emerging approaches
such as high throughput techniques, trascriptome analysis
and next-generation DNA sequencing method.
Here, we will discuss the recent literature on the role of
biological markers in AD, summarizing the status in this
field and focusing on the most promising genetic and
biochemical biomarkers.
2. Pathogenesis of Alzheimer’s Disease and
Amyloid Hypothesis
AD is the most frequent cause of dementia affecting more
than 53 million people [4] worldwide and is often a multi-
factorial disease. The key clinical features of AD are pro-
gressive memory loss and cognitive decline. The disorder is
histopathologically and morphologically characterized by
deposition of extracellular plaques (Ab42) and intracellular
neurofibrillary tangles (tau) that are believed to play
an active role in the neurodegenerative process of AD [5].
The amyloid cascade hypothesis articulated by J. Hardy is
the central paradigm for the cause of AD and was promi-
nent in the field of AD research [6]. The core of this
hypothesis is an imbalance between the production and
the clearance of Ab in the brain [7]. The proteolytically
derived product of amyloid precursor protein (APP) Ab42
is the main constituent of the amyloid plaques. Ab is gen-
erated by sequential actions of b-secretase and g-secretase
on APP through an amyloidogenic pathway and there are
several truncated Ab isoforms in the brain. The enzyme
accountable for the b-secretase activity is b-site APP-cleav-
ing enzyme 1 (BACE1) and an increased activity have been
found in cases of prodromal AD [8,9]. Detailed description
of the main causes of the AD have been extensively
reviewed elsewhere [10] but it is essential to point out that
the amyloid cascade hypothesis has less support today.
Recently, many patients with severe AD showed no plaques
at the post-mortem analysis and conversely the plaques
may be found in the elderly without dementia [11]. It has
now proposed that other forms of Ab such as soluble Ab
oligomers cause AD [12] and interestingly it has been
reported that the composition and levels of postmortem
CSF biomarkers can differ from that of antemortem
[13,14]. Another neuropathological hallmark of AD are
inclusions of microtubule-associated protein tau that is the
major constituent of neurofibrillary tangles. The abnormal
hyperphosphorylation of tau causes dysfunctions in the
axonal transport mainly due to the generation of insoluble
aggregates during the formation of neurofibrillary tangles.
Tau undergoes to post-traslational modifications [15] that
may be involved in the pathology of the disease. In particu-
lar, it can be phosphorylated on multiple sites (to date 39
different sites verified) [16], which seems to be important
in reducing the affinity of tau for microtubules [17]. As
proposed by the amyloid hypothesis, changes in tau and
resultant neurofibrillary tangles formation are triggered by
toxic concentrations of Ab. Despite the fact that the link
between Ab and tau is still unclear, several hypotheses
have been proposed [18]. In order to develop new therapies
and since it is possible that changes in phosphokinases
c o u l db ei n v o l v e di nt a up h o s p o r y l a t i o n ,m a n yp r o t e i n
kinase such as glycogen synthase kinase 3b (GSK3b),
cyclin-dependent kinase 5 (CDK5), extracellular signal-
related kinase 2 (ERK2), have been investigated as targets
of treatments to reduce tau phosphorylation. Therefore,
the cascade which leads to the formation of phosphorylated
tau may contribute to synaptic and neuronal loss and preli-
minary work which aimed to reduce tau phosphorylation
has shown that tau kinase inhibitors block neurofibrillary
tangles formation in tau transgenic mouse but clinical test-
ings are still under investigation [19].
AD has a widespread and complex molecular back-
ground, and different molecular changes occur in the dis-
order. Therefore, it has been suggested that there is no
single molecular event which leads to AD but it is caused
by different and multiple parallel mechanisms. Recently
new findings supported the amyloid hypothesis [20], but
also the tau pathology. In addition, important information
and experimental evidence have emerged. One of these is
the mitochondrial dysfunction with degeneration of mito-
chondria in neurons [21], but also phenomena such as
inflammatory mechanisms, oxidative stress [22], vascular
homeostasis, lipid metabolism [4] followed also by altera-
tions in energy metabolism and antioxidant defense
system.
3. Genetic of Alzheimer’s disease
Genetically, AD is a complex and heterogeneous disorder
which involves a combination of genes that need to be
identified and validated. Additionally, the genetic risk of
developing AD is around 70% [23] but familial AD
accounts for less than 1% of the AD burden [7]. Generally,
AD is divided into two forms: (1) early onset familial AD
with Mendelian inheritance and (2) late onset AD named
sporadic form, but it is necessary to emphasize that this his-
torical dichotomy remains elusive for many aspects. How-
ever, among the genetic causes implicated in disease risk,
three genes have been essential in our understanding of AD
mechanism. Particularly, mutations in APP, presenilin-1
gene (PS1), and presenilin-2 gene (PS2) cause an autosomal
dominant form of AD of young onset. These alterations are
responsible for increase in Ab generation or in the levels of
Ab42. Novel and fast high throughput approach such as
DNA and RNA microarrays have led to the identification of
multiple genes involved in different stages of AD [2], but it
is important to avoid misidentification of false positive and
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and familial genes are reported in table 1 and in addition to
PS1 and PS2 that affect the accumulation of b-amyloid
protein several other genes may have a role in the clearance
or uptake of Ab.
Recent studies indicate that the over-expression or
some polymorphisms of phosphokinases, such as dual-
specificity tyrosine phosphorylation-regulated kinase 1A
(DYRK1A) contribute to an early onset of neurofibrillary
degeneration, b-amyloidosis, neuronal loss [24] and this
gene might be associated to the Ab production and tau
phosphorilation [25].
Apolipoprotein E (APOE) localized on chromosome 19
is the major genetic risk factor that account for the late
onset AD; in particular the E4 variant (APOE4) of APOE
gene is particularly important for sporadic AD but
APOE4 is also associated with an earlier onset of the dis-
ease [26,27]. Three majors alleles (E2, E3, E4) are present
on the chromosome but subjects carrying the E4 allele
have increased amyloid deposition and recently it has
been shown that the E4 allele affects memory and execu-
tive function [28]. APOE4 is the most reliable locus for
AD but recent genome wide association studies (GWAS)
have demonstrated other risk loci, in particular a study of
16 000 individuals showed association with loci of clus-
terin (CLU) and phosphatidylinositol-binding clathrin
assembly protein (PICALM) genes [29]. Functionally,
CLU is involved in clearance and aggregation of Ab but
also in Ab fibrillization [30,31].P I C A L Mp l a y sar o l ei n
clathrin-mediated endocytosis [32], synaptic transmis-
sion, and in the removal of apoptotic cells [33,34].
To date, several GWAS have been performed with sev-
eral genes implicated in AD risk and progression rate and
it is established by an emerging consensus that common
genetic variation plays an important role in the etiology of
AD. However, even though GWAS are critical in defining
rare sequence variants that predispose to both early and
late onset forms of AD, it is necessary to replicate genetic
associations which would require case/control comparison
of several hundreds of individuals.
The first considerable finding based on large scale
sequencing technologies was GRB2-associated binding
protein 2 (GAB2). GAB2 binds growth factor receptor-
bound protein 2 (GRB2), which in turn can bind APP and
both presenilins [35] but GAB2 is also associated with
increased tau phosphorylation and its effect is most pro-
nounced on carriers of the APOE4 allele [36]. In addition,
new significant susceptibility loci are the complement
receptor 1 gene (CR1) [37], a key inflammatory receptor
protein activated in AD [38] and the bridging integrator 1
gene (BIN1) [39], which encodes an adaptor protein
involved in receptor mediated endocytosis [40]. Interest-
ingly, CLU, CR1 and PICALM have received much
attention because supported by independent follow up
studies [41].
The latest contribution to identify new susceptibility
loci through GWAS was made by the Genetic and Envir-
onmental Risk in Alzheimer’s Disease Consortium 1
(GERAD1) which showed ATP-binding cassette, sub-
family A, member 7 (ABCA7) and membrane-spanning
4A (MS4A) gene cluster being two new AD associated
loci. Further, the same study revealed genome-wide sig-
nificance for CD2-associated protein (CD2AP), encoding
ephrin receptor A1 (EPHA1) and Siglec-3 (CD33) that is
a member of the sialic-acid-binding immunoglobulin-like
lectins family and these three loci consisted in a follow-
up indicative of association with AD [42].
Noticeably, other robust results come from the Alzhei-
mer Disease Genetics Consortium (ADGC) that performed
G W A So fl a t eo n s e tA Da n da c c o r d i n g l yw eh a v en o w
overall ten late onset AD susceptibility loci (APOE, CR1,
CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP and
ABCA7) that enhance our understanding of the genetic
architecture of AD [43]. Other genes that could be consid-
ered to have a potential relevance in the risk for AD are
genetic variants involved in inflammation. Notably, inter-
leukins (IL1A, IL1B, and IL6) are one of the strongest
evidence of inflammatory agents that increase the risk of
AD and significant polymorphisms are implicated in AD as
demonstrated in several case/control studies [44]. It is
widely accepted that genetic variation is important for the
pathogenesis of AD and several researchers have tried to
find out polymorphisms that may be related with it but
convincing outcomes have not emerged yet. However, very
recently Kennedy et al. reported that the brain-derived
neurotrophic factor (BDNF) Val66Met (rs6265) poly-
morphism may have a genetic susceptibility mechanism for
AD. These findings highlighted that the effect of BDNF
Val66Met polymorphism confers risk of AD in an age-
dependent manner [45]. In addition, genetic variants in the
sortilin-related receptor (SORL1), involved in trafficking of
APP, increases the risk of AD. Recent data of genetic asso-
ciations suggest that changes in one of its homologs, the
sortilin-related VPS10 domain containing receptor 1
(SORCS1) may affect the risk of AD [46]. It is also interest-
ing to mention a new study that analyzed the region of
APOE and of the adjacent gene translocase of outer mito-
chondrial membrane 40 (TOMM40) that are strongly asso-
ciated with AD. Two poliymorphisms for APOE and
TOMM40, respectively rs429358 and rs2075650, reached
genome wide significance and showed association with Ab
and t-tau/Ab ratios [47]. In order to investigate the genetic
associations between the inflammatory mediator tumor
necrosis factor-a (TNF-a) and AD, a detailed meta-analy-
sis of polymorphisms in TNF-a was reviewed by Caruso
et al. The study analyzed the association between 5 TNF-a
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Familial Genes Locus Functions
APP 21q21.3 APP gene encodes a membrane protein cleaved by secretase. Mutations in App locus causes autosomal dominant early
onset AD and cerebroarterial amyloidosis.
PS1 14q24.2 PS1 is involved in APP processing and mutations can interfere the production of Ab42 and to form plaques. Numerous
alternatively spliced transcript variants encoding different isoforms have been identified for this gene.
PS2 1q42.13 Regulate APP processing as a part of the a-secretase complex. Familial mutations can change the production of Ab42.
Risk Genes
APOE 19q13.32 ApoE regulates the normal catabolism of triglyceride-rich lipoprotein constituents. APOE binds Ab and it is involved in
Ab clearance. Subjects carrying the E4 allele have an increased amyloid burden.
TAU 17q21.31 The transcript undergoes complex alternative splicing and tau exists as six splice isoforms. The mutations can alter
microtubule binding efficacy.
DYRK1A 21q22.13 DYRK1A is localized in the critical region of chromosome 21 and is involved in tau and APP phosphorylation. Firstly the
activity is upregulated by Ab and APP phosphorylation result in increased amyloidogenic processing with BACE
interaction.
GSK3b 3q13.33 The overexpression of this gene may be relevant for AD. GSK-3 phosphorylates tau and presenilin-1, which are involved
in the development of AD. The phosphorylation of tau leads to tangle formation and APP cleavage products can
activate GSK3b resulting increased tau phosphorylation.
New GWAS
Genes
CLU 8p21.1 Clusterin is a chaperone molecule involved in clearence, aggregation and fibrillization of Ab. It is associated with the
progression of AD.
PICALM 11q14.2 Phosphatidylinositol binding clathrin assembly protein is associated with an increased risk of developing AD. PICALM
plays a role in synaptic trasmission and may be involved in Ab clearence. The protein is present in endosomes
connected with AD.
CR1 1q32.2 This gene is a member of the receptors of complement activation (RCA) family, precisely the complement C3b protein,
a key inflammatory protein activated in AD.
BIN1 2q14.3 This gene encodes several isoforms of a nucleocytoplasmic adaptor protein involved in endocytosis. BIN1 could have an
effect on Ab production and/or the clearance of Ab.
ABCA7 19p13.3 This gene is a member of the superfamily of ATP-binding cassette (ABC) transporters and is highly expressed in brain,
particularly in the microglia. ABCA7 inhibit b-amyloid secretion in cultured cells overexpressing APP.
MS4A 11q12.2 The genes in the MS4A cluster are locolized on chromosome 11 and encode proteins with at least 4 potential
transmembrane domains but do not have specific function yet.
CD2AP 6p12.3 C2AP encodes a scaffolding molecule that regulates the actin cytoskeleton and is involved in the regulation of receptor-
mediated endocytosis.
EPHA1 7q35 EPHA1 is a member of the ephrin receptor subfamily of the protein-tyrosine kinase family. It is implicated in synaptic
development and plasticity but also axon guidance. Other functions have been proposed.
CD33 19q13.41 CD33 molecule belongs to the family of sialic acid-binding, immunoglobulinlike lectins. CD33 regulate the functions in
the adaptive and innate immune systems both involved into the inflammatory reactions observed in the brains of AD
patients.
Genes in genomic location are in according to Ensembl cytogenetic band.
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and suggested a specific genetic effect of the -850 single
nucleotide polymorphism (SNP) on the AD risk [48].
Finally, it is important to provide further genetic bio-
m a r k e r sf o rt h ef u t u r eb u ta tt h es a m et i m ei sv i t a lt o
develop an accurate biomarker panel able to predict AD
risk but also identify the pathways involved in the disor-
der and potential drug targets.
4. Biochemical markers for AD
The CSF is an optimal source of AD biomarkers because it
is in intimate contact with the extracellular space of the
brain and can reflect biochemical changes and metabolic
processes that occur in the course of the disease. The diag-
nostic use of CSF for AD is difficult because collecting
CSF requires an invasive treatment by lumbar puncture.
Thus, other body fluids may be useful for AD diagnosis
but also to monitor the progression of the disorder and to
search for biomarkers. Metabolic products and proteins
such as albumin, immunoglobulins, transferrin and a2-
macroglobulin can be detect in plasma or serum but
requires very sensitive methods because their total content
especially in serum is very low.
4.1 Experimental approach to detect biochemical markers
in AD
Here we will provide a brief overview on the main meth-
ods that are currently used to enhance our understanding
of AD and develop a biomarkers panel that could support
clinical diagnosis. All these methods have advantages and
disadvantages but it is important to standardize the entire
workflow including sample processing and instrument
setup. There are several issues in the search of AD bio-
marker discovery but in order to develop novel diagnostic
strategies to diagnose and monitor AD progression it is
essential to complement ‘omics’ disciplines with other tra-
ditional methods. The major proteomics biomarker dis-
covery methods are two-dimensional gel electrophoresis
(2-DE) that provide high sensitivity and mass spectrometry
(MS) based techniques.
For instance, the characterization of the human CSF
proteome typically requires combined approach such as
2D-polyacrylamide gel electrophoresis (PAGE) with
matrix-assisted laser desorption/ionization combined with
time of flight MS (MALDI-TOF-MS) and liquid chroma-
tography combined with electrospray ionization (LC-ESI-
MS). Also the technology surrounding biomarker analysis
in blood is developing rapidly and the increasing need of
biomarkers in clinical trials has been faciliated by high
throughput multiplex platform [49,50]. In addtion, there
are several AD biomarker studies with surface enhanced
laser desorption ionization (SELDI)-TOF-MS which pro-
vides an high throughput protein expression profile analy-
sis [51]. Furthermore, most of proteomics methods for
protein quantification are based on chemical labelling with
stable isotope and different labelling strategies are avail-
able, such as isotope tagged relative and absolute quantita-
tion (iTRAQ) [52], tandem mass tag (TMT) [53], isotope
coded affinity tag (ICAT) [54] and isotope coded protein
label (ICPL) [55]. In addition, antibody array provide an
high throughput method to analize multiple biomarkers
simultaneously. This assay, which was based on xMAP
technology (Luminex, Austin, TX, USA) will replace
enzyme linked immunosorbent assays (ELISA) in the mea-
surement of the biomarkers.
Molecular imaging techniques improve diagnostic accu-
racy by reflecting brain function and single positron emis-
sion computed tomography (SPECT), PET, MRI provide
relevant clinical results. PET using Pittsburg compound
(PIB) allows the direct visualization of Ab plaque burden
in the brain when the patients are still alive. Structural
MRI provide measures of brain atrophy [56] related to the
degree of cognitive impairment [57]. Also the evolution of
computational approaches could help the discovery of bio-
markers that cause the disorder and the bioinformatics
tools may reveal the high complexity of pathological
mechanisms evidencing the protein networks that lead to
AD.
4.2 CSF Biomarkers
The concentrations of several proteins in CSF reflects with
good diagnostic accuracy the pathophysiological features
of the disease. Particularly, there is an “AD signature” in
the CSF [58] because the measurements of numerous stu-
dies have found that patients with AD have a marked
increase in CSF levels of total tau (t-tau) and phosphory-
lated tau (p-tau) but characteristically show a reduction in
Ab42. Combining the various CSF markers may be useful
to differentiate different forms of dementia [59] and to
predict the conversion from mild cognitive impairment
(MCI) to AD. In this perspective, Trojanowski et al. with
targeted proteomic screen revealed novel CSF biomarkers
that can improve the distinction between AD and non AD
cases. Specifically, they identified some analytes including
Ab42, resistin and thrombospondin-1 that are associated
with AD [60]. In 2010, the same author argued that Ab42
is the most sensitive CSF biomarker for AD, with a sensi-
tivity of 96.4% [61]. In addition, even though the combined
analysis of Ab42, t-tau and p-tau are approved in clinical
diagnostic tools, some researchers have asserted that has
less predictive value in preclinical testing [62].
Recent studies have been focused on the investigation of
truncated Ab isoforms and experimental data showed a
novel pathway where short isoforms are generated by b-
secretase and a-secretase and long isoforms are produced
by g-secretase [63]. Interestingly, the levels of Ab (1-37,
-38, -39, -40, -42) gave a 91% sensitivity and a 64% specifi-
city in predicting the development of AD from MCI
Davinelli et al. Immunity & Ageing 2011, 8:7
http://www.immunityageing.com/content/8/1/7
Page 5 of 10during a follow up study [64]. Other CSF biomarkers that
m a yb ev a l u a b l ef o rA Da r en e u r o n a la n ds y n a p t i c
proteins. Notably, visinin-like protein 1 (VLP-1), a calcium
sensor protein expressed in high abundance in neurons,
was found markedly increased in CSF of patients with AD
[65]. Furthermore, an immunoassay for growth associated
protein (GAP43), revealed increased levels of the protein
in CSF from patients with AD [66]. AD specific changes in
the CSF proteome have been found in many studies. For
istance, variations that have been reported in AD include
altered levels of a-1-antitrypsin, a-1b glycoprotein,
APOA-I, APOE, retinol binding protein, vitamin D-bind-
ing protein, prostaglandin H2 D isomerase and transthyre-
tin (TTR) [67-72]. Interestingly, the presence of APOE4
allele is associated with increased deposition of Ab42 in
the brain and decreased CSF level of Ab42 [73].
Emerging evidence indicates that oxidative damage is
involved in AD. For instance, lipid peroxidation affects
the generation of F2-isoprostanes whose levels are often
increased in the CSF of patients with AD [74]. Lipid per-
oxidation products have been found in brain, CSF and
plasma from mammalian models with AD [75] and
GWAS have identified new risk genes that are linked to
lipid metabolism such as CLU also known as apolipopro-
tein J (ApoJ) [29].
Although there are several inflammatory biomarkers
reported in CSF, none of them can be considered to have
diagnostic or predictive value. However, some candidate
CSF biomarkers of inflammation that showed increased
levels in AD are TNF-a [76], monocyte chemotactic pro-
tein-1 [77], interferon g-inducible protein 10, IL-8 [78], IL-
6 [79], transforming growth factor-b (TGFb) [80], vascular
endothelial growth factor (VEGF) [79] and others but
detecting changes of inflammatory molecules in CSF
require larger scale of replication in cohorts of patients
because of their low levels in the CSF.
Recently, using an unbiased proteomics approach (2D-
DIGE LC-MS/MS), Fagan and co-workers identified four
novel CSF biomarkers for AD (NrCAM, YKL-40, chromo-
granin A, carnosinase I). Notably, these markers can
improve the diagnostic panel accuracy especially of Ab42
and tau and may have the utility to better discriminate
early symptomatic AD from cognitive normalcy but also
other dementing conditions [81].
In a future perspective on the progress of CSF examina-
tion it might be useful to focus on post-translational modi-
fications that have not been widely studied in CSF
proteome studies. For example, phosphorylation is the
most common tau post-translational modification
described but other post-translational modifications have
received much less attention and it is likely that additional
modifications are required for the formation of tau aggre-
gates. Various kinases and phosphatases regulate tau
phosphorylation [82] suggesting their potential involve-
ment in the development of new therapeutic drugs for AD.
Currently, in CSF several candidate biomarkers have
been found but their applicability to improve the diag-
n o s i so fA Do rt od i s c o v e rn e wd r u gt a r g e t sh a v en o t
established yet. However, numerous studies have been
shown that the most promising biomarkers for AD in
CSF include the combined analysis of Ab42, t-tatu and
p-tau that allows sensitive, reliable and specific diagnosis
of AD identifying prodromal AD in cases of MCI.
4.3 Biomarkers in blood
In the last years many efforts were done to find disease
specific and reliable blood biomarkers and different candi-
date such as a1-antitrypsin, complement factor H, a-2-
macroglobulin, ApoJ and ApoA-1 have been proposed.
However, the verification of changes in the levels of these
molecules is difficult to verify in independent studies. In
addition, it is significant to note that in the search for
blood biomarkers correlated with AD the identification
should be performed on the strength of accepted CSF
markers, such as Ab and tau related biomarkers. Further-
more, several documented evidence suggested that in the
blood there is a protein signature related with AD but also
in some way a transcript signature that might be relevant
to predict and monitor the disease and increase reliability
of the diagnosis. Although the study of the transcriptome
as a potential source of biomarkers in blood could have
many advantages the evidence of a transcript signature in
blood are scant and its utility in AD diagnosis remains to
be clarified. Table 2 lists the main biomarkers related to
AD mentioned in this review.
In 2007, with a combined multivariate analysis of 18
plasma signaling and inflammatory proteins (e.g. IL-1a,
IL-3, TNF-a) Ray and colleagues identified a profile that
was indicative of AD and predicted AD in patients with
MCI [50]. Plasma Ab was examined in different studies
but provided opposing data because Ab binds several
plasma proteins resulting in epitope masking and other
analytical interferences [83]. The role of inflammation
with microglia activation is believed to play a role in AD
pathogenesis but the presence of inflammatory markers
in serum or plasma is unclear. Inflammatory molecules,
such as IL-1b, TNF-a, IL-6, C-reactive protein, a1-antic-
hymotrypsin showed contrasting results [84]. Seshadri
and colleagues in the Framingham study observed that
high levels of peripheral blood mononuclear cell
(PBMC) of the inflammatory cytokines such as IL-1 or
TNF-a are associated with an increased risk of develop-
ing AD [85].
Noteworthy, Teunissen et al. evaluated 29 serum bio-
markers for inflammation, cholesterol and homocysteine
metabolism, and brain specific proteins. This panel
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strated to be a suitable combination to discriminate AD
from controls [86]. Several evidence have documented
that cholesterol metabolism plays a role in AD [87]. Total
serum cholesterol may be a marker of AD because high
concentration of serum cholesterol is associated with
increased risk of incident AD [88]. In the brain monocytes
migrate through the blood-brain barrier (BBB) interacting
with specific cell adhesion molecules (CAM). Several
CAMs on monocytes are activated during the inflamma-
tory and neurodegenerative response. Therefore, these
could be useful as biomarkers in AD. Humpel and
Table 2 Main pathway and biomarkers AD related cited in this review
Pathway Biomarker Potential association with AD
Signal
transduction
GSK3b GSK3b integrates a variety of intracellular and extracellular pathways and appears to be increased in the AD
brain. GSK3b is regulated by phosphorylation and is the major tau kinases.
CDK5 Cdk5 plays a role in processes of neural development, synaptic signalling, learning and can influence tau
phosphorylation indirectly via regulation of GSK3b.
ERK2 The phosphorylation of tau by ERK2 induces tau to acquire biochemical properties of AD. ERK2 was detected
in neurofibrillary tangles.
DYRK1A Dyrk1A is abnormally expressed in AD and recently it has been found to be associated with neurofibrillary
tangles in sporadic AD.
PKC PKC has been implicated in memory mechanisms and is also involved in the processing of APP. The activators
of PKC lead to increased processing of APP by the a-secretase pathway.
VLP-1 Visinin-like protein 1 concentration is significantly altered in the CSF of AD patients and ia is associated with
fibrillar tangles in AD brains.
Oxidative
stress
F2-isoprostanes Incresed levels of F2-isoprostanes are found in AD plasma and CSF.
Inflammation Interleukins Interleukins are consistently detected in the brains of AD and polymorphisms are implicated in AD. The activity
in AD contributes to synaptic dysfunction and loss, and later, neuronal death.
TNF-a TNF-a has a central role in AD pathogenesis. The levels are increased in CSF and correlated with clinical
deterioration.
C-reactive
protein
C-reactive protein has been found to be associated with AD in histopathological and longitudinal studies. It is
associated with increased risk of AD.
a-1-
antichymotrypsin
a-1-antichymotrypsin participates in the inflammatory cascade of AD and enhances the formation of amyloid-
fibrils.
a2-
macroglobulin
a2-macroglobulin has an important role in AD etiopathology. The main ability is to mediate the clearance and
degradation of Ab.
Homocysteine Hyperhomocysteinaemia is a risk factor for AD and mental decline.
ICAM-1 ICAM-1 is expressed on cerebrovascular endothelium and neuritic plaques in brain of AD patients and seems
to be implicated in the process of neuro-degeneration.
VCAM-1 Abnormal levels of VCAM-1 levels have been found in individuals with AD as well as other cell adhesion
molecules.
Lipid
metabolism
Total cholesterol High concentration of serum cholesterol is associated with increased risk of incident AD.
APOE APOE E2, E3, and E4 alleles alter the likelihood of developing AD and cerebral amyloid angiopathy.
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tin are significantly reduced in AD patients [89].
A growing body of evidence demonstrates that plasma
concentration of vascular cell adhesion molecule-1
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-
1) are increased in AD. In addition, endothelial vasodila-
tory such as endothelin (ET-1), adrenomedullin (ADM),
and atrial natriuretic peptide (ANP), as well as sphingoli-
pids are altered in mild AD and MCI suggesting sensitivity
of these biomarkers for early detection and diagnosis [90].
Another potential biomarker important for AD diagno-
sis because involved in tau phosphorylation, is the protein
kinase C (PKC). The PKC function is involved in memory
processes in animal models [91] and appears altered in red
blood cells and lymphocytes of AD patients [92]. By inhi-
biting GSK3b, PKC reduces tau phosphorylation and neu-
rofibrillary tangles formation [93] representing a potential
target for the development of disease modifying drugs.
In summary, according to the diagnostic and prognos-
tic point of view, the most promising markers in AD
diagnosis to be associated with Ab and tau include a1-
antitrypsin, a-2-macroglobulin, apo lipoproteins and
TTR.
Conclusively, it seems clear that the combinations of dif-
ferent biomarkers can improve the diagnosis of AD but
t h em a r k e r si nt h eC S Fa n db l o o da r en o te n o u g ha n d
other molecules are abnormally processed in AD.
Overall, by analyzing 13 different brain regions of AD
affected patients Korolainen et al. demonstrated changes
in 93 proteins in association with the disease [94]. These
proteins showed quantitative differences and/or post-
translational modifications in cognitive impairment in
early and late AD. According to the gene ontology (GO)
classification these proteins are involved in oxidation-
reduction (12), glycolysis (8), transport (8), metabolic pro-
cesses (7), protein folding (6), the response to unfolded
proteins (5) and cell proliferation (5). 56 of them are cyto-
plasmic, 28 mitochondrial, 20 nuclear and 16 cytosolic
proteins. Finally, three of them are synaptic proteins
(synaptosomal-associated protein-25 (SNAP-25), synapto-
tagmin and syntaxin-binding protein) which present
altered expression or modification.
5. Concluding remarks
We have highlighted different biomarkers that may be
important for the detection and differential diagnosis of
AD. It is clear that many questions remain to be answered
especially because we know only few evidence about the
relationships between these biomarkers and the develop-
ment of the disease. Although the combined analysis of
Ab, t-tau and p-tau can be used to diagnose AD, it is
important to characterize the core of biomarkers involved
in the prodromal phase of AD but also in the presympto-
matic stage of the disease. For this purpose only the
combination of several biomarker derived from CSF and
other body fluids will be efficacious to define a specific sig-
nature of AD. The measurement of AD biomarkers in the
CSF or by structural and functional imaging and genetics
methods improves diagnostic accuracy but also the pro-
spect for blood based biomarkers is attractive. Taken
together these tools have revealed the effective importance
of molecular mechanism that contribute to pathological
changes and neurodegeneration. For instance, these pro-
cesses are oxidative stress, overproduction of reactive
oxygen species, changes in ubiquitination, reorganization
in the cytoskeletal proteins, production of misfolded pro-
tein and many others. Furthermore, it is important to
implement common protocol and to standardize the ultra-
sensitive analytical methods for experimental design and
generation data.
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